Royalty Pharma plc
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $7.10B | $10.25B | $1.54B |
| FY2022 | $6.12B | $9.53B | $1.71B |
| FY2023 | $6.14B | $10.08B | $477.0M |
| FY2024 | $6.61B | $10.34B | $929.0M |
| FY2025 | $8.57B | $9.71B | $618.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $7.10B | $10.25B | $1.54B |
| FY2022 | $6.12B | $9.53B | $1.71B |
| FY2023 | $6.14B | $10.08B | $477.0M |
| FY2024 | $6.61B | $10.34B | $929.0M |
| FY2025 | $8.57B | $9.71B | $618.7M |